AzTrials
AzTrials

HypotensionPhase 4NCT03664037

Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries

A Phase 4 study testing Dexamethasone phosphate in people with Hypotension, run by Ain Shams University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Based on the data that DEX increases the TPR and may decrease the expression of serotonin the investigator conducted this study to test the hypothesis that the prophylactic intravenous infusion (IVI) of DEX can attenuate the hypotensive effect of spinal anesthesia in elderly population. Read more about this study

Who is it for?
Ages 60 years and olderHealthy volunteers can take part
Conditions the study is for
Hypotension
What is being tested?
Dexamethasone phosphate
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
110 participants
Where
1 siteEgypt
Study dates
1 Mar 2018to 31 Aug 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 110 patients aged 60 years or older
  • of the American Society of Anesthesiologists (ASA) physical status I, II or III
  • undergoing lower limb orthopedic surgeries.
  • A written informed consent was obtained from all patients to participate in the study.

Who cannot join

  • Patients with contraindication to SA (e.g.- coagulopathy,
  • thrombocytopenia,
  • allergy to local anesthetic agent)
  • and those on steroid or serotonin related medications (e.g. selective serotonin reuptake inhibitor) were excluded.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Ibrahim Mamdouh Esmat

    Heliopolis, Cairo Governorate, 11361

Other trials in Egypt

About this study

Official title: Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries: a Double Blind, Placebo-controlled Study

Based on the data that DEX increases the TPR and may decrease the expression of serotonin the investigator conducted this study to test the hypothesis that the prophylactic intravenous infusion (IVI) of DEX can attenuate the hypotensive effect of spinal anesthesia in elderly population.

Read the detailed description

After approval by the institute ethics committee, this study was conducted at Ain-Shams university hospitals, from the 1st of March 2018 till the 31st of August 2018 and on 110 patients aged 60 years or older of the American Society of Anesthesiologists (ASA) physical status I, II or III. A written informed consent was obtained from all patients to participate in the study. Patients with contraindication to SA (e.g. coagulopathy, thrombocytopenia, allergy to local anesthetic agent) and those on steroid or serotonin related medications (e.g. selective serotonin reuptake inhibitor) were excluded.

This study was designed to be a randomized, placebo-controlled, double-blinded parallel study. Following enrollment, patients were randomized into 2 equal groups; the D group, (n=55) each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline [NS]) intravenous infusion (IVI) over 15 min 2 hours preoperatively and the C group, (n=55) each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively. Randomization was done using computer-generated number table of random numbers in a 1:1 ratio in opaque and sealed envelope (SNOSE). The assigned treatment was written on a card and sealed in opaque envelopes consecutively numbered. These envelopes were opened just immediately before infusing the medication in the patient's room. The study drugs were prepared by the hospital pharmacy and follow-up of patients were conducted by the anesthesia residents not involved in any other part of the study.

Patients were prepared by fasting (8 h for solid foods and 4 hours for clear fluids) before anesthesia and were hydrated intravenously before the procedure. Patients were hooked to a portable monitor (Non-invasive blood pressure and pulse oximetry) in their rooms from which baseline measurements (heart rate(HR), systolic(SAP), diastolic(DAP) and mean arterial blood pressure(MAP)) were recorded just before administration of the study medication.

As soon as the patient arrived in the operating room pulse oximetry, electrocardiogram monitoring, and non-invasive arterial pressure measurement were started, and patients were sedated by 1mg of IV midazolam. An18-gauge intravenous cannula was inserted, and slow infusion of 0.9% sodium chloride solution was commenced to keep the vein opened and didn't exceed the volume of 200 mL during the study period (during giving anesthesia and for 20 minutes thereafter). Lumbar puncture was performed with the patient in a sitting position and the subarachnoid space was punctured at the L3-L4 or L4-L5 level using 25 gauge Quincke spinal needle under aseptic condition. After identification of the subarachnoid space3 mL of 0.5% hyperbaric bupivacaine solution (Marcaine® Spinal 0.5% Heavy; Sunny pivacaine, Manufactured by Sunny Pharmaceutical - Cairo - Egypt) were injected over 60 seconds.

Immediately after completing the subarachnoid injection, patients were positioned supine on the operating table. This was followed by assessment of sensory block every 5 minutes with a cold sensation test (using alcohol swab). At the same time points, the level of motor blockade was assessed (according to the Modified Bromage Score(13) with the following categories: 0=No motor block; 1=Inability to raise extended leg; able to move knees and feet; 2=Inability to raise extended leg and move knee; able to move feet and 3=Complete block of motor limb), and the HR, SAP, DAP and the MAP were measured and recorded every 5 minutes after SA and for 4 readings thereafter.

Hypotension was considered if there was 25% decrease below the baseline for MAP and was treated with IV crystalloid (Ringer solution) and incremental IV 5 mg doses of ephedrine. Bradycardia was considered if the heart rate < 50 beats/min and was treated with IV atropine (0.01mg/kg).

The study end point was 20 minutes after giving the subarachnoid block during which positioning, raising tourniquet or surgical incision was not be allowed.

Data collection:

The hemodynamic parameter values before anesthesia and the values recorded after the blockade were used for the analysis. Analysis was done by comparing the obtained values at each study time point and by comparing the minimal values recorded within the 20 minutes following the blockade as well. When ephedrine or atropine administration was necessary, only the values obtained before this medication was used. Surgical procedure, positioning the patient or application of tourniquet was not allowed during the study period.

Outcomes:

The primary outcome variable in this study was proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure.

The secondary outcomes were:

  • The characteristics of the motor blockade.
  • The changes in the MAP, SAP, and DAP values in both patient groups, which were recorded before blockade and at 5-minute intervals after the block (till 20 minutes following the blockade).
  • The changes in the heart rate (HR).
  • The total ephedrine consumption was given to correct hypotension.
  • The total atropine consumption was given to correct bradycardia. 3-Analysis of Data:

Depending on Baig et al.,2017(14) who found that the hypotension rate in ondansetron and normal saline groups 7.5% and 28.3% respectively, and assuming the power= 0.80 and α=0.05 and by using PASS 11th release the minimal sample size for an equal size controlled clinical trial was 50 in each group. The investigator recruited 55 in each group for possible attrition(15).

The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013.

Conditions
Hypotension
Being tested
Dexamethasone phosphate, Placebo
Medical subject headings
Hypotension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dexamethasone phosphateDrug

    each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline [NS]) intravenous infusion (IVI) over 15 min 2 hours preoperatively

  • PlaceboDrug

    each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively

Study groups in NCT03664037
Study groupRoleWhat they receive
D group, (n=55)Active comparatorNot described
Receives: Drug: Dexamethasone phosphate
C group, (n=55)Placebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure.

    proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure.

    Measured: The first 20 minutes after induction of SA before start of surgical procedure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2018
  2. Study start1 Mar 2018
  3. Primary completion31 Aug 2018
  4. Study completion31 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03664037
Sponsor's protocol ID
R 46 / 2018
Status last verified
Jul 2023
First submitted
7 Sep 2018
Last updated
21 Jul 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Ashoor TM, Hussien NS, Anis SG, Esmat IM. Dexamethasone blunts postspinal hypotension in geriatric patients undergoing orthopedic surgery: a double blind, placebo-controlled study. BMC Anesthesiol. 2021 Jan 11;21(1):11. doi: 10.1186/s12871-021-01232-w.

    PubMed 33430772

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Dexamethasone phosphate in people with Hypotension, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure. (time frame: The first 20 minutes after induction of SA before start of surgical procedure.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03664037, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in